FIP GLOBAL COMMITMENT TO ACTION ON PRIMARY HEALTH CARE

The Hague, 25 October 2021

We commit to:

1. Support the Declaration of Astana on Primary Health Care in achieving universal health coverage through provision of high-quality, people-centred, safe integrated, accessible and affordable health and pharmaceutical care services;

2. Develop and provide successful and sustainable models of care for the management of communicable, vector-borne and non-communicable diseases, health promotion, disease prevention, screening and referral, and ensure patient safety taking into consideration changing populations, growing numbers of older adults and their associated health needs;

3. Develop academic capacity through engagement with pharmaceutical higher education policy makers, relevant stakeholders and empower pharmaceutical and academic leaders to strengthen primary health care;

4. Optimise the current and future pharmaceutical workforce with adequate capacity and capability to support effective provision of primary health care, through interprofessional collaboration within the entire health and care workforce;

5. Transform pharmaceutical services and delivery of primary health care through needs-based pharmaceutical education strategies and interprofessional continuing education and training;

6. Continue to ensure patients and communities receive appropriate, effective, safe, people-centred, timely, accessible, transparent, evidence-based, equitable and integrated pharmaceutical care and information from the right health care team, and in the right conditions;

7. Deliver the medicines expert’s role in public health by fighting against antimicrobial resistance and promoting rational use of medicines, thereby reducing medication-related harm for individuals and populations;
8. Design enabling workplace environments for the entire pharmaceutical workforce so that they are able to do their jobs efficiently, with maximised performance, well-being and safety, thereby ensuring communities are satisfied with the services they receive;

9. Shape primary health care delivery by adopting digital health technologies in pharmaceutical care (such as use of big data, electronic medical records, and medical and assistive devices that can accelerate diagnosis) to support decision-making and facilitate delivery of care;

10. Support assessment, evaluation and improvement of the quality of primary health care, as well as other pharmaceutical services, through evidence-based quality improvement interventions;

11. Promote and advocate effective and efficient allocation of resources, remuneration, incentive and purchasing systems to strengthen provision of integrated pharmaceutical services centred around primary health care and public health;

12. Continue to engage public and private sector stakeholders and partners in the delivery of integrated pharmaceutical services through building understanding, delivering strategy, fostering relations, aligning structures and nurturing trust;

13. Generate knowledge and evidence through conducting primary health care-oriented research and health outcomes assessment to inform the advancement of pharmaceutical interventions and expertise;

14. Ensure monitoring and evaluation systems are in place to implement our commitment as well as to track how the decisions, actions and investments affect pharmacists’ primary health care provision, and the health status of individuals and populations; and

15. Be national, regional and global pharmacy ambassadors in the attainment of the FIP Development Goals, with the ultimate aim of achieving the United Nations Sustainable Development Goals by 2030, through provision of essential patient care and safe, effective, quality and affordable essential medicines and vaccines for all.

Together we can and we will achieve universal health coverage, good health and well-being for all, leaving no one behind.

The FIP Bureau:
Mr Dominique Jordan (Switzerland)
President

Dr Catherine Duggan (Netherlands)
Chief executive officer

Dr Carmen Peña (Spain)
Immediate past president

Mr Luís Lourenço (Portugal)
Professional secretary

Prof. Giovanni Pauletti (USA)
Scientific secretary

Prof. Ralph Altiere (USA)
Chair of FIP Education

Prof. Ross McKinnon (Australia)
Chair of the Board of Pharmaceutical Sciences
Mr Paul Sinclair (Australia)
Chair of the Board of Pharmaceutical Practice

Prof. Parisa Aslani (Australia)
Vice president

Mr Carlos Lacava (Uruguay)
Vice president

Ms Manjiri Gharat (India)
Vice president

Ms Samira Shammas (Jordan)
Vice president

Prof. Ashok Soni (UK)
Vice president

Mr Lars-Åke Söderlund (Sweden)
Vice president

Prof. Hiroshi Suzuki (Japan)
Vice president